Objective - Restoring a normal quality of life (QOL) should be the goal of treatments of gastro-esophageal reflux (GER) without severe esophagitis. In this analysis, carried out within the frame of a clinical study comparing a topical anti-inflammatory gel to a placebo, we assessed the relevance of the MOS SF-36 questionnaire in patients suffering from GER without severe esophagitis, and compared the scores of the studied patients to those of a representative sample of the French general population. Patients and methods - The patients had to suffer from GER symptoms for at least 2 months, with no or mild (≤ grade 1) esophagitis endoscopy. They were randomized to be given a 4 week treatment either with a topical gel containing gaiazulene and dimeticone or a placebo gel. Patients were asked to complete a symptom diary during the study, which allowed the calculation of mean symptom scores. The MOS SF-36 questionnaire was administered at baseline (d0) and after 4 weeks of treatment (d28). Results-Two hundred and thirty three patients were enrolled in the sudy. At baseline, QOL scores were impaired in both groups. After 4 weeks of treatment: the treated patients displayed better improvement in all MOS SF-36 domains compared with the placebo group. The QOL profile in the treated group reached the level of the French reference population, while it remained impaired in the placebo group. Conclusion - This analysis evidenced the relevancy of the MOS SF-36 questionnaire to assess the impact of GER without severe esophagitis on QOL.Moreover, it demonstrated the capacity of the studied topical treatment to restore a normal QOL to the patients. Objective-Restoring a normal quality of life (QOL) should be the goal of treatments of gastro-esophageal reflux (GER) without severe esophagitis. In this analysis, carried out within the frame of a clinical study comparing a topical anti-inflammatory gel to a placebo, we assessed the relevance of the MOS SF-36 questionnaire in patients suffering from GER without severe esophagitis, and compared the scores of the studied patients to those of a representative sample of the French general population. Patients and methods - The patients had to suffer from GER symptoms for at least 2 months, with no or mild (≤ grade 1) esophagitis endoscopy. They were randomized to be given a 4 week treatment either with a topical gel containing gaiazulene and dimeticone or a placebo gel. Patients were asked to complete a symptom diary during the study, which allowed the calculation of mean symptom scores. The MOS SF-36 questionnaire was administered at baseline (d0) and after 4 weeks of treatment (d28) Results-Two hundred and thirty three patients were enrolled in the sudy. At baseline, QOL scores were impaired in both groups. After 4 weeks of treatment: the treated patients showed better improvement in all MOS SF-36 domains compared with the placebo group . The QOL profile in the treated group reached the level of the French reference population, while it remained impaired in the placebo group. Conclusion - This analysis evidence of the relevancy of the MOS SF-36 questionnaire to assess the impact of GER without severe esophagitis on QOL.Moreover, it demonstrated the capacity of the studied topical treatment to restore a normal QOL to the patients.